Brief: Camp4 Therapeutics Initiates GLP Toxicology Studies For Cmp-Syngap-01
01/10/2025 14:51
Oct 1 (Reuters) - CAMP4 Therapeutics Corp CAMP.O: CAMP4 THERAPEUTICS INITIATES GLP TOXICOLOGY STUDIES FOR CMP-SYNGAP-01 Source text: ID:nGNX7Zk3Wp Further company coverage: CAMP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CAMP4 Therapeutics
See all newsBrief: Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder
Camp4 Therapeutics Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Camp4 Therapeutics Q2 Loss Per Share Misses Estimates On Non: cash derivative charge
Camp4 Therapeutics Corp Expected To Post A Loss Of 21 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation